adults

Norgine welcomes TGA registration in Australia of IFINWIL (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]Norgine welcomes TGA registration in Australia of IFINWIL (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

Norgine welcomes TGA registration in Australia of IFINWIL (eflornithine) for adults and children diagnosed with high-risk neuroblastoma (HRNB)[1]

IFINWIL®: now TGA registered in AustraliaChildren diagnosed with neuroblastoma are on average just 2 years old2The average survival rate of children…

1 month ago
Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Ozempic (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

Ozempic® improved maximum walking distance by 13% vs placebo in adults with type 2 diabetes and peripheral artery disease (PAD)…

2 months ago
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary EndpointAxsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

Demonstrated substantial and statistically significant improvement in ADHD symptoms as measured by the AISRS total score compared to placebo (p=0.039,…

2 months ago
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathyargenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy

December 27, 2024 01:00 ET  | Source: argenx SE VYVDURA® now approved for at-home self-injection in Japan for both generalized…

5 months ago
Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with InsomniaNxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Adults with Insomnia

December 18, 2024 21:35 ET  | Source: Nxera Pharma Tokyo, Japan and Cambridge, UK, 19 December 2024 – Nxera Pharma…

5 months ago
Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CMLLonger-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Longer-term data for Novartis Scemblix reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2%…

5 months ago
Worldwide English Proficiency Index Reports Persistent Global Decline With Weaker Skills in Women and Young adultsWorldwide English Proficiency Index Reports Persistent Global Decline With Weaker Skills in Women and Young adults

Worldwide English Proficiency Index Reports Persistent Global Decline With Weaker Skills in Women and Young adults

ZURICH, Nov. 13, 2024 /PRNewswire/ -- EF Education First (EF), a global provider of culturally immersive education, released the 2024 edition of…

6 months ago